BeiGene becomes BeOne
Company marks milestone with new name and Swiss redomiciliation
BeOne Medicines Ltd., a global oncology company formerly known as BeiGene, Ltd., has announced that its new name and redomiciliation to Switzerland are officially in effect. “BeOne represents more than a name change—it’s not only a reflection of who we are today as a leading global oncology company, but also our ambition to redefine what’s possible in oncology,” said John V. Oyler, Co-Founder, Chairman, and CEO at BeOne.
What is the new name of BeiGene, Ltd.?
BeiGene, Ltd. has officially changed its name to BeOne Medicines Ltd.
Why did the company choose the name BeOne?
According to Oyler, BeOne reflects the company’s identity as a global oncology leader and its ambition to “unite patients, families, scientists, physicians, governments, and other oncology public health stakeholders around the world in our shared mission against cancer.”
What progress has BeOne made in oncology?
BeOne highlights the growth of BRUKINSA as the backbone of its hematology franchise, the expansion of its PD-1 inhibitor TEVIMBRA, and a pipeline of over 50 investigational assets.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
